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A Sc(OTf)3-catalyzed intramolecular tandem 1,5-hydride transfer/cyclization process to construct 3-
amino-3-carboxy-tetrahydroquinoline derivatives has been developed. The methodology gives access
to a range of relatively complex tetrahydroquinolines (tetracyclic and pentacyclic heterocycles bearing
spirocyclic skeleton and two stereogenic centers) in good to excellent yields with diastereoselectivities
ranging from 57:43 to 73:27. The synthetic utility of the method was also demonstrated by an efﬁcient
ring opening derivatization reaction.
 2013 Elsevier Ltd. All rights reserved.Fig. 1. Some biologically active compounds containing a tetrahydroquinoline skeleton.1. Introduction
Tetrahydroquinoline scaffolds belong to an important class of
heterocycles and are found in a number of naturally occurring and
biologically active compounds (Fig. 1).1 Some tetrahydroquinoline
compounds are useful building blocks for the synthesis of many
pharmaceutical and agrochemical reagents, as well as for the total
synthesis of some natural products.1,2 In accord with the impor-
tance, there have been a lot of interests in the development of
synthetic methodologies to access various tetrahydroquinoline
compounds. In this regard, diverse tetrahydroquinoline derivatives
have been designed and prepared with metal-based and organo-
catalytic strategies.3 Despite that important progress in the ﬁeld of
the synthesis of diverse tetrahydroquinoline derivatives has been
made, to the best of our knowledge, the construction of a class of
promising tetrahydroquinoline compounds, which possess a 3-
amino-3-carboxy-tetrahydroquinoline scaffold and can be charac-
terized as a kind of cyclic a-quaternary a-amino acids,4 remains
unexplored so far. Given the fact that different class of tetrahy-
droquinoline skeletons may show promise as certain biologically@cioc.ac.cn, yuanweicheng@
All rights reserved.relevant compounds, hence, the development of elegant and efﬁ-
cient protocol for preparing 3-amino-3-carboxy-tetrahydroquino-
line compounds is highly desirable.The functionalization of sp3 CeH bond via intramolecular tan-
dem 1,5-hydride transfer/cyclization process represents an impor-
tant topic in synthetic organic chemistry.5 As shown in Scheme 1, in
that process, the CeH bond a to the nitrogen atom is ﬁrstly cleaved
via a 1,5-hydride shift to form an iminium intermediate, and then
Table 1
Screening of reaction conditionsa
Entry Solvent Catalyst Time (h) Drb Yield (%)c
1 Mesitylene 24 62:38 32
W.-Y. Han et al. / Tetrahedron 69 (2013) 7019e70257020undergoes a cyclization reaction to afford tetrahydroquinoline
scaffold. Much effort has been devoted to this tandem trans-
formation by applying it for the construction of various tetrahy-
droquinoline derivatives.6 We recently reported an efﬁcient FeCl3-
catalyzed stereoselective intramolecular 1,5-hydride transfer/cy-
clization reaction for generating structurally diverse spirooxindole
tetrahydroquinolines (Scheme 2 (a)).7 Enlightened by the related
literature5,6 and the fact that alkylidene azlactones belong to a type
of highly reactive Michael acceptors,8 we reasoned that with ap-
propriate alkylidene azlactone derivatives as substrates and certain
Lewis acids as catalysts via a 1,5-hydride transfer and subsequent
cyclization, the reaction should offer the possibility to access a new
family of tetrahydroquinoline derivatives bearing spirocyclic skel-
eton, which could be further transformed to 3-amino-3-carboxy-
tetrahydroquinoline compounds (Scheme 2 (b)). In parallel with
our efforts to develop new catalytic system for the synthesis of
heterocyclic compounds,7,9 herein, we present the results of our
endeavors on this subject.
Scheme 1. The functionalization of sp3 CeH bond via 1,5-hydride transfer/cyclization
process.2 Mesitylene Sc(OTf)3 3 65:35 85
3 Mesitylene Mg(ClO4)2 5 60:40 25
4 Mesitylene Zn(OTf)2 5 65:35 26
5 Mesitylene CuOTf 5 69:31 18
6 Mesitylene NiCl2 5 63:37 38
7 Mesitylene FeCl3 5 59:41 71
8 Mesitylene Ni(OAc)2 5 ndd <10
9 Mesitylene Cu(OTf)2 5 nd <10
10 Mesitylene AgNO3 5 55:45 76
11 DCE Sc(OTf)3 24 nd <10e
12 Toluene Sc(OTf)3 24 nd <10f
13 CH3CN Sc(OTf)3 24 nd Tracee
14 Mesitylene Sc(OTf)3 5 66:34 82g
15 Mesitylene Sc(OTf)3 5 66:34 83h
16 Mesitylene Sc(OTf)3 1 69:31 90i
a Unless otherwise speciﬁed, all reactions were carried out in sealed-tube with 1a
(0.1 mmol) and 20 mol % catalyst in 2.0 mL of speciﬁed solvent at 190 C for the
stated time.
b Determined by 1H NMR.
c Isolated yield of diastereomeric mixture.
d Not determined.
e Run at 100 C.
f Run at 150 C.
g 5 mol % of Sc(OTf)3 was used.
h 10 mol % of Sc(OTf)3 was used.
i 30 mol % of Sc(OTf)3 was used. DCE¼1,2-dichloroethane.Scheme 2. (a) Intramolecular tandem 1,5-hydride transfer/cyclization process for the
synthesis of spirooxindole tetrahydroquinolines. (b) Strategy for the synthesis of 3-
amino-3-carboxy-tetrahydroquinolines with intramolecular tandem 1,5-hydride
transfer/cyclization process.2. Results and discussion
To test our hypothesis, we decided to initiate our study by using
(Z)-alkylidene azlactone 1a10 as a model substrate for screening of
the reaction conditions (Table 1). A control experiment revealed
that the planed 1,5-hydride transfer/cyclization process could take
place in mesitylenewithout any catalyst, but a harsh condition high
to 190 C in sealed-tube was needed. Even so, the expected product
2a could be isolated in only 32% yield with diastereoselective ratio
(dr) of 62:38 after 24 h (Table 1, entry 1). However, to our delight,
adding 20 mol % Sc(OTf)3 into the reaction system, we were able to
isolate the product 2a in 85% yield with 65:35 dr after 3 h (Table 1,
entry 2). After further examination to some other Lewis acids, itwas observed that Mg(ClO4)2, Zn(OTf)2, CuOTf, NiCl2, FeCl3,
Ni(OAc)2, Cu(OTf)2, and AgNO3 were inferior to Sc(OTf)3 for the
conversion (Table 1, entries 3e10). These results reveal that, to
a large extent, the tolerance of the Lewis acids to the high tem-
perature and the acidity of the Lewis acids play a dramatic effect on
the reactivity. Afterward, we investigated the inﬂuence of the sol-
vent, mesitylene proved to be the best choice as reaction medium
for the 1,5-hydride transfer/cyclization process (Table 1, entry 2 vs
entries 11e13). And then, the catalyst loading was tested, con-
ducting the experiment with 5 mol % and 10 mol % catalyst loading,
respectively, it was found that the reactions showed analogous
diastereoselectivity and reactivity (Table 1, entries 14 and 15). Ul-
timately, increasing the catalyst loading to 30mol % allowed the full
conversion of the startingmaterial within 1 h, giving the product 2a
in 90% yield with 69:31 dr (Table 1, entry 16).Having identiﬁed a useful set of reaction conditions, we next
examined the reaction scope by subjecting various (Z)-alkylidene
azlactones 1ben10 to the Sc(OTf)3-catalyzed intramolecular 1,5-
hydride transfer/cyclization process. The results are summarized
in Table 2, generally, the expected 3-amino-3-carboxy-tetrahy-
droquinoline derivatives 2ben bearing spirocyclic skeleton were
able to be obtained in moderate to excellent yields (37e99%) with
diastereoselectivities ranging from 57:43 to 73:27. For the piperi-
dine derived substrates 1bef, it was found that the reaction pro-
ceeded smoothly, leading to the expected heterocyclic products
2bef with good results independently of the substitution pattern
on the Ar group. Nevertheless, under the same reaction conditions,
the related morpholine derived substrates 1geh required a rela-
tively prolonged reaction time for delivering the corresponding
3-amino-3-carboxy-tetrahydroquinoline derivatives 2g and 2h.
W.-Y. Han et al. / Tetrahedron 69 (2013) 7019e7025 7021Gratifyingly, perhaps due to the superior hydride donor capability
of benzylic over aliphatic secondary CeH bond, the tetrahy-
droisoquinoline derivatives 1ien more easily underwent the
intramolecular 1,5-hydride transfer/cyclization reaction than those
piperidine and morpholine derived substrates, giving the corre-
sponding products 2ien in almost quantitative yields after shorter
reaction time with only 5 mol % Sc(OTf)3. Additionally, we also
surveyed the reactivity of the corresponding pyrrolidine derived
substrates. Unfortunately, the reaction was very complicated as
monitored by thin layer chromatography (TLC) analysis and no
desired product was obtained. We surmised that the failure of this
reaction was probably caused by the harsh reaction temperature.
However, when we tried to perform the reaction at 100 C with
corresponding pyrrolidine-based substrate, the reaction still did
not take place. Nevertheless, we also found that the starting ma-
terials, which incorporate acyclic amines, such as corresponding N-
methyl-1-phenylmethanamine-based substrate, were not able to
tolerate the reaction conditions and could not give the expected
products (data not shown).Table 2
Sc(OTf)3-catalyzed intramolecular 1,5-hydride transfer/cyclization process of 1a
a For the synthesis of 2b-h, the reactions were carried out in 
sealed-tube under argon atmosphere with 1 (0.2 mmol) and 30 
mol % Sc(OTf)3 in 4.0 mL mesitylene at 190 oC for the 
specified time; for the synthesis of 2i-n, the reactions were 
carried out in sealed-tube under argon atmosphere with 1 (0.2 
mmol) and 5 mol % Sc(OTf)3 in 4.0 mL mesitylene at 190 oC 
for the specified time. 
b Isolated yield of diastereomeric mixture, the same note applies 
to all of the other products.
c Determined by 1H NMR, the same note applies to all of the 
other products.
Fig. 2. The stereochemistry analysis of the products.With a library of relatively complex products 2aen (tetracyclic
and pentacyclic heterocycles bearing spirocyclic skeleton and
two stereogenic centers) in hand, the synthetic utility of themethodology was further demonstrated by the transformations of
some products into the relevant ring opening compounds (Scheme
3). We chose products 2i, 2k, and 2n as the research subjects re-
gardless of the substitution pattern on the Ar group. Upon the
treatment of these products with sodiummethoxide inmethanol at
room temperature for 10 min, respectively, we could readily obtain
the corresponding ring opening compounds 3i, 3k, and 3n in
quantitative yield and almost no change in diastereoselectivity
(Scheme 3). It is worth noting that these ring opening compounds
possess a special 3-amino-3-carboxy-tetrahydroquinoline scaffold,
particularly bearing amino and carboxyl two potential points for
structural diversiﬁcation as a prelude to library synthesis.
Scheme 3. Transformation of the products 2i, 2k, and 2n to corresponding ring
opening compounds.Finally, considering the fact that no reaction occurred at the
stereogenic center in 2n during its transformation into compound
3n (Scheme 3), we reasoned that the compounds 2n and 3n should
possess the same relative conﬁguration. For the isomers A, as
shown in the left of Fig. 2, there is a trans relationship between the
Ha and the amide group, it should no NOE effect between the Ha
and the Hc of amide group. On the other hand, for the isomers B, as
shown in the right of Fig. 2, there is a cis relationship between the
Hb and the amide group and it should give the NOE effect between
the Hb and the Hc of amide group. Consequently, based on the NOE
experiments the stereochemistry for the major and minor di-
astereoisomers of 3n is able to be determined11 As shown in Fig. 2,
the major diastereoisomers of 3n were assigned as isomers A and
the minor diastereoisomers of 3n were assigned as isomers B.
Thereby, the relative conﬁguration of product 2n should be able to
be determined with logical deduction. Assuming via a common
reaction pathway in the construction of compounds 2aen, the
stereochemistry of these 3-amino-3-carboxy-tetrahydroquinoline
products in this work was assigned by analogy.3. Conclusion
In conclusion, we have developed a Sc(OTf)3-catalyzed intra-
molecular tandem 1,5-hydride transfer/cyclization reaction for the
construction of a range of 3-amino-3-carboxy-tetrahydroquinoline
derivatives. This protocol could afford the tetracyclic and penta-
cyclic tetrahydroquinoline products, containing a spirocyclic skel-
eton and two stereogenic centers, in good to excellent yields with
diastereoselectivities ranging from 57:43 to 73:27. Additionally, we
revealed that these relatively complex products could be readily
transformed to cyclic a-quaternary a-amino acid analogous, and
W.-Y. Han et al. / Tetrahedron 69 (2013) 7019e70257022the relative conﬁgurations of the products were tentatively de-
termined by NOE experiments and derivatization. The method
described here provides an efﬁcient access to 3-amino-3-carboxy-




Reagents were purchased from commercial sources and were
used as received unless mentioned otherwise. 1H NMR chemical
shifts were reported in parts per million (d) relative to tetrame-
thylsilane (TMS)with the solvent resonance employed as the internal
standard. Data were reported as follows: chemical shift, multiplicity
(s¼singlet, d¼doublet, t¼triplet,m¼multiplet, br¼broad, br s¼broad
singlet), coupling constants (Hertz), and integration. 13C NMR
chemical shifts were reported in ppm (d) from tetramethylsilane
(TMS) with the solvent resonance as the internal standard. Melting
points were recorded on a Buchi Melting Point B-545 unit.
4.2. Representative procedure for the synthesis of (Z)-alkyli-
dene azlactones
To a solution of 2-ﬂuorobenzaldehyde (4.96 g, 40 mmol) and
K2CO3 (6.36 g, 46 mmol) in DMF (40 mL) was added piperidine
(4.56 mL, 46 mmol). The resulting reaction mixture was heated
under reﬂux until complete consumption of 2-ﬂuorobenzaldehyde.
The reaction mixture was allowed to cool to room temperature,
diluted with water, and extracted with ethyl acetate. The combined
organic extracts were washed with a saturated NH4C1 solution and
concentrated under reduced pressure. The product 2-(piperidin-1-
yl)benzaldehyde was utilized for next step without puriﬁcation.
Glycine (5.0 g, 66.7 mmol) was dissolved in 50 mL of 10% NaOH
solution. BzCl (10.79 mL, 93.0 mmol) was added to the solution and
stirred vigorously for 30 min. Crushed ice (60 g) was added to the
solution and then concentrated HCl was added dropwise until the
mixture was acidiﬁed (pH 2e3). The precipitate was ﬁltrated and
washed with distilled water until neutrality. The product 2-
benzamidoacetic acid was obtained after drying in vacuum.
A mixture of 2-(piperidin-1-yl)benzaldehyde (0.946 g, 5 mmol)
and 2-benzamidoacetic acid (0.896 g, 5 mmol) was heated in 95 C
with the addition of NaOAc (2.5 mmol) and Ac2O (5 mmol). After
completion of the reaction, 2 mL ethanol was added to the mixture
and was stirred for 10 h at room temperature. The solid was ﬁltered
off, washed with water, and ice-cold ethanol. The crude product
was recrystallized from toluene to give the corresponding (Z)-
alkylidene azlactones 1a (Note: For the preparation of compounds
1ben, the corresponding crude products were recrystallized from
ethanol to give the desired products 1ben).
4.2.1. (Z)-2-Phenyl-4-(2-(piperidin-1-yl)benzylidene) oxazol-5(4H)-
one (1a). Orange solid, yield 50%; mp 146.0e147.1 C; 1H NMR
(300 MHz, CDCl3), d (ppm): 1.61e1.65 (m, 2H), 1.77e1.84 (m, 4H),
2.95e2.98 (m, 4H), 7.07 (d, J¼8.1 Hz, 1H), 7.15 (t, J¼7.5 Hz, 1H), 7.39
(t, J¼7.5 Hz, 1H), 7.49e7.61 (m, 3H), 7.76 (s, 1H), 8.17 (d, J¼7.5 Hz,
2H), 8.68 (d, J¼7.8 Hz, 1H); 13C NMR (75 MHz, CDCl3), d (ppm): 24.1,
26.3, 55.0, 118.9, 122.5, 125.8, 127.2, 128.1, 128.8, 129.2, 132.0, 132.1,
132.9, 133.0, 155.9, 162.6, 168.0. HRMS (ESI-TOF) calcd for
C21H21N2O2 [MþH]þ: 333.1598; found: 333.1599.
4.2.2. (Z)-4-(2-(Piperidin-1-yl)benzylidene)-2-o-tolyloxazol-5(4H)-
one (1b). Red solid, yield 31%; mp 128.1e129.4 C; 1H NMR
(300 MHz, CDCl3), d (ppm): 1.63 (d, J¼5.1 Hz, 2H), 1.78e1.85 (m,
4H), 2.83 (s, 3H), 2.97 (t, J¼5.1 Hz, 4H), 7.06e7.16 (m, 2H), 7.26e7.48
(m, 4H), 7.77 (s,1H), 8.08 (d, J¼7.8 Hz,1H), 8.67 (d, J¼7.8 Hz,1H); 13CNMR (75 MHz, CDCl3), d (ppm): 22.8, 24.1, 26.3, 55.0, 118.9, 122.5,
124.2, 126.1, 127.2, 128.8, 130.1, 131.9, 132.0, 132.1, 132.2, 132.7, 140.4,
155.9, 162.7, 167.9. HRMS (ESI-TOF) calcd for C22H23N2O2 [MþH]þ:
347.1754; found: 347.1748.
4.2.3. (Z)-4-(2-(Piperidin-1-yl)benzylidene)-2-p-tolyloxazol-5(4H)-
one (1c). Yellow solid, yield 61%; mp 172.9e174.0 C; 1H NMR
(300 MHz, CDCl3), d (ppm): 1.63 (t, J¼5.4, 2H), 1.76e1.84 (m, 4H),
2.45 (s, 3H), 2.96 (t, J¼5.4 Hz, 4H), 7.06 (d, J¼8.1 Hz, 1H), 7.14 (t,
J¼7.5 Hz, 1H), 7.30e7.41 (m, 3H), 7.72 (s, 1H), 8.05 (d, J¼8.1 Hz, 2H),
8.67 (d, J¼7.8 Hz, 1H); 13C NMR (75 MHz, CDCl3), d (ppm): 21.8, 24.1,
26.3, 55.0, 118.9, 122.5, 123.0, 127.2, 128.1, 128.5, 129.6, 131.8, 132.2,
132.9, 143.9, 155.7, 162.8, 168.2. HRMS (ESI-TOF) calcd for
C22H23N2O2 [MþH]þ: 347.1754; found: 347.1753.
4.2.4. (Z)-2-(4-Methoxyphenyl)-4-(2-(piperidin-1-yl)benzylidene)
oxazol-5(4H)-one (1d). Yellow solid, yield 31%; mp 161.8e162.0 C;
1H NMR (300 MHz, CDCl3), d (ppm): 1.60e1.66 (m, 2H), 1.76e1.83
(m, 4H), 2.95 (t, J¼5.1 Hz, 4H), 3.89 (s, 3H), 6.99e7.07 (m, 3H),
7.14e7.37 (m, 2H), 7.68 (s, 1H), 8.11 (dd, J1¼1.8 Hz, J2¼6.9 Hz, 2H),
8.66 (dd, J1¼1.5 Hz, J2¼7.8 Hz, 1H); 13C NMR (75 MHz, CDCl3),
d (ppm): 24.1, 26.3, 54.9, 55.5, 114.3, 118.1, 118.8, 122.4, 127.3, 127.6,
130.1, 131.6, 132.3, 132.8, 155.6, 162.5, 163.5, 168.3. HRMS (ESI-TOF)
calcd for C22H23N2O3 [MþH]þ: 363.1703; found: 363.1703.
4.2.5. (Z)-2-(3-Fluorophenyl)-4-(2-(piperidin-1-yl)benzylidene) ox-
azol-5(4H)-one (1e). Orange solid, yield 46%; mp 151.2e152.3 C;
1H NMR (300 MHz, CDCl3), d (ppm): 1.62 (d, J¼5.1, 2H), 1.76e1.81
(m, 4H), 2.96 (t, J¼5.1 Hz, 4H), 7.07 (d, J¼8.1 Hz, 1H), 7.16 (d,
J¼7.5 Hz,1H), 7.27 (t, J¼5.4 Hz,1H), 7.37e7.40 (m,1H), 7.47e7.50 (m,
1H), 7.78 (s,1H), 7.85 (d, J¼9.3 Hz,1H), 7.94 (d, J¼7.8 Hz,1H), 8.63 (d,
J¼7.8 Hz, 1H); 13C NMR (75 MHz, CDCl3), d (ppm): 24.1, 26.3, 55.1,
114.8 (d, J¼23.8 Hz, 1C), 119.0, 120.0 (d, J¼21.3 Hz, 1C), 122.5, 123.9
(d, J¼3.1 Hz, 1C), 126.9, 128.0 (d, J¼8.4 Hz, 1C), 130.2, 130.6 (d,
J¼7.9 Hz, 1C), 131.6, 132.3, 133.1, 156.0, 161.4, 164.3, 164.4 (d,
J¼491.4 Hz, 1C). HRMS (ESI-TOF) calcd for C21H20FN2O2 [MþH]þ:
351.1503; found: 351.1510.
4.2.6. (Z)-2-(4-Bromophenyl)-4-(2-(piperidin-1-yl)benzylidene) ox-
azol-5(4H)-one (1f). Orange solid, yield 35%; mp 163.6e165.1 C;
1H NMR (300 MHz, CDCl3), d (ppm): 1.62 (d, J¼5.7, 2H), 1.79 (t,
J¼4.8, 4H), 2.96 (t, J¼5.1, 4H), 7.06 (d, J¼8.1 Hz, 1H), 7.14 (t, J¼7.5 Hz,
1H), 7.40 (t, J¼7.5 Hz,1H), 7.65 (d, J¼8.4 Hz, 2H), 7.76 (s, 1H), 8.01 (d,
J¼8.4, 2H), 8.62 (d, J¼7.8, 1H); 13C NMR (75 MHz, CDCl3), d (ppm):
24.1, 26.3, 55.0, 118.9, 122.5, 124.7, 127.0, 127.9, 129.4, 129.8, 131.7,
132.1, 132.2, 133.0, 156.0, 161.8, 167.7. HRMS (ESI-TOF) calcd for
C21H20BrN2O2 [MþH]þ: 411.0703; found: 411.0696.
4.2.7. (Z)-4-(2-Morpholinobenzylidene)-2-phenyloxazol-5(4H)-one
(1g). Yellow solid, yield 43%;mp 187.6e189.0 C; 1HNMR (300MHz,
CDCl3), d (ppm): 3.00 (s, 4H), 3.92 (s, 4H), 7.09 (d, J¼7.8 Hz, 1H), 7.21
(t, J¼7.5 Hz, 1H), 7.43 (t, J¼7.2 Hz, 1H), 7.49e7.60 (m, 3H), 7.75 (m,
1H), 8.16 (d, J¼6.0 Hz, 2H), 8.69 (d, J¼7.5 Hz, 1H); 13C NMR (75 MHz,
CDCl3), d (ppm): 53.7, 67.0, 118.8, 123.5, 125.6, 127.2, 128.1, 128.2,
128.8, 132.1, 132.6, 133.1, 133.2, 154.1, 163.1, 167.8. HRMS (ESI-TOF)
calcd for C20H19N2O3 [MþH]þ: 335.1390; found: 335.1384.
4.2.8. (Z)-2-(3-Fluorophenyl)-4-(2-morpholinobenzylidene) oxazol-
5(4H)-one (1h). Yellow solid, yield 45%; mp 165.2e166.6 C; 1H
NMR (300 MHz, CDCl3), d (ppm): 3.00 (t, J¼4.2 Hz, 4H), 3.92 (t,
J¼4.2 Hz, 4H), 7.10 (d, J¼8.1 Hz, 1H), 7.19e7.29 (m, 2H), 7.41e7.50
(m, 2H), 7.78 (s, 1H), 7.84 (d, J¼9.0 Hz, 1H), 7.93 (d, J¼7.8 Hz, 1H),
8.65 (d, J¼7.8 Hz,1H); 13C NMR (75MHz, CDCl3), d (ppm): 53.8, 67.0,
114.9 (d, J¼23.8 Hz, 1C), 118.9, 120.1 (d, J¼21.3 Hz, 1C), 123.5, 123.9
(d, J¼3.0 Hz, 1C), 127.1, 127.8 (d, J¼47.7 Hz, 1C), 129.0, 130.6 (d,
J¼7.9 Hz, 1C), 132.2, 132.4, 133.2, 154.3, 161.9 (d, J¼3.6 Hz, 1C), 162.7
W.-Y. Han et al. / Tetrahedron 69 (2013) 7019e7025 7023(d, J¼246.2 Hz, 1C), 167.4. HRMS (ESI-TOF) calcd for C20H18FN2O3
[MþH]þ: 353.1296; found: 353.1297.
4.2.9. (Z)-4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzylidene)-2-
phenyloxazol-5(4H)-one (1i). Yellow solid, yield 50%; mp
161.6e162.9 C; 1H NMR (300 MHz, CDCl3), d (ppm): 3.08 (t,
J¼5.7 Hz, 2H), 3.35 (t, J¼5.7 Hz, 2H), 4.30 (s, 2H), 7.12e7.26 (m, 6H),
7.42 (d, J¼6.6 Hz, 1H), 7.51e7.61 (m, 3H), 7.78 (s, 1H), 8.20 (d,
J¼7.2 Hz, 2H), 8.73 (d, J¼7.8 Hz, 1H); 13C NMR (75 MHz, CDCl3),
d (ppm): 29.2, 53.3, 54.1,119.1,123.0,125.8,126.0,126.3,126.4,127.2,
128.2, 128.8, 128.9, 129.1, 132.0, 132.4, 133.1, 133.2, 134.3, 134.4,
154.2, 162.9, 167.9. HRMS (ESI-TOF) calcd for C25H21N2O2 [MþH]þ:
381.1598; found: 381.1602.
4.2.10. (Z)-4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzylidene)-2-o-
tolyloxazol-5(4H)-one (1j). Yellow solid, yield 34%;mp 151.0e152.4 C;
1H NMR (300MHz, CDCl3), d (ppm): 2.85 (s, 3H), 3.10 (t, J¼5.4 Hz, 2H),
3.36 (t, J¼5.7 Hz, 2H), 4.30 (s, 2H), 7.11e7.26 (m, 6H), 7.33e7.50 (m,
4H), 7.80 (s, 1H), 8.10 (d, J¼7.8 Hz, 1H), 8.73 (d, J¼7.8 Hz, 1H); 13C NMR
(75 MHz, CDCl3), d (ppm): 22.8, 29.2, 53.3, 54.0, 119.1, 122.9, 124.2,
125.9, 126.1, 126.3, 126.4, 127.2, 128.4, 129.0, 130.2, 131.9, 132.1, 132.3,
132.5, 132.9, 134.3, 140.5, 154.2, 163.1, 167.7. HRMS (ESI-TOF) calcd for
C26H23N2O2 [MþH]þ: 395.1754; found: 395.1746.
4.2.11. (Z)-4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzylidene)-2-p-tol-
yloxazol-5(4H)-one (1k). Yellow solid, yield 42%; mp 190.0e191.2 C;
1HNMR (300MHz, CDCl3), d (ppm): 2.47 (s, 3H), 3.09 (d, J¼5.1 Hz, 2H),
3.34 (t, J¼5.4 Hz, 2H), 4.30 (s, 2H), 7.12e7.28 (m, 6H), 7.34 (t, J¼7.8 Hz,
2H), 7.43 (t, J¼7.5 Hz, 1H), 7.75 (s, 1H), 8.08 (d, J¼7.8 Hz, 2H), 8.74 (d,
J¼7.5Hz,1H); 13CNMR (75MHz, CDCl3), d (ppm): 21.8, 29.2, 53.2, 54.0,
119.0, 122.9, 125.9, 126.3, 126.4, 127.2, 128.0, 128.2, 129.0, 129.6, 131.8,
132.5, 133.1, 134.3, 144.0, 154.1, 163.0, 168.0. HRMS (ESI-TOF) calcd for
C26H23N2O2 [MþH]þ: 395.1754; found: 395.1749.
4.2.12. (Z)-4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzylidene)-2-
(4-methoxyphenyl)oxazol-5(4H)-one (1l). Yellow solid, yield 35%;
mp 192.0e193.2 C; 1H NMR (300 MHz, CDCl3), d (ppm): 3.08 (t,
J¼5.1 Hz, 2H), 3.34 (t, J¼5.7 Hz, 2H), 3.90 (s, 3H), 4.29 (s, 2H), 7.02 (d,
J¼8.7 Hz, 2H), 7.10e7.26 (m, 6H), 7.41 (t, J¼7.8 Hz, 1H), 7.70 (s, 1H),
8.13 (d, J¼8.7 Hz, 2H), 8.72 (d, J¼7.8 Hz, 1H); 13C NMR (75 MHz,
CDCl3), d (ppm): 29.2, 53.2, 54.0, 55.5, 114.4, 114.5, 118.0, 119.0,
122.9, 125.9, 126.3, 126.4, 127.1, 127.4, 129.0, 130.2, 131.6, 132.7,
133.0, 134.3, 154.0, 162.8, 163.6, 168.1. HRMS (ESI-TOF) calcd for
C26H23N2O3 [MþH]þ: 411.1703; found: 411.1688.
4.2.13. (Z)-4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzylidene)-2-
(3-ﬂuorophenyl)oxazol-5(4H)-one (1m). Yellow solid, yield 29%; mp
168.5e169.7 C; 1H NMR (300 MHz, CDCl3), d (ppm): 3.08 (d,
J¼4.5 Hz, 2H), 3.33 (d, J¼5.1 Hz, 2H), 4.29 (s, 2H), 7.12e7.33 (m, 7H),
7.41e7.54 (m, 2H), 7.80 (s, 1H), 7.87 (d, J¼8.7 Hz, 1H), 7.96 (d,
J¼7.5 Hz, 1H), 8.70 (d, J¼7.8 Hz, 1H); 13C NMR (75 MHz, CDCl3),
d (ppm): 29.2, 53.4, 54.0, 114.8 (d, J¼24.4 Hz, 1C), 119.1, 120.1 (d,
J¼21.2 Hz, 1C), 123.0, 123.9 (d, J¼2.9 Hz, 1C), 126.0, 126.3 (d,
J¼12.1 Hz, 1C), 126.9, 127.9 (d, J¼8.5 Hz, 1C), 129.0, 129.7, 130.6 (d,
J¼7.9 Hz, 1C), 132.0, 132.2, 133.2, 134.2 (d, J¼3.4 Hz, 1C), 154.4, 161.8,
162.7 (d, J¼246.1 Hz, 1C), 167.4. HRMS (ESI-TOF) calcd for
C25H20FN2O2 [MþH]þ: 399.1503; found: 399.1499.
4.2.14. (Z)-2-(4-Bromophenyl)-4-(2-(3,4-dihydroisoquinolin-2(1H)-
yl)benzylidene)oxazol-5(4H)-one (1n). Yellow solid, yield 51%; mp
170.0e171.6 C; 1H NMR (300 MHz, CDCl3), d (ppm): 3.08 (t,
J¼5.1 Hz, 2H), 3.34 (t, J¼5.7 Hz, 2H), 4.29 (s, 2H), 7.10e7.26 (m, 6H),
7.43 (t, J¼7.5 Hz, 1H), 7.66 (d, J¼8.4 Hz, 2H), 7.79 (s, 1H), 8.03 (d,
J¼8.5 Hz, 2H), 8.69 (d, J¼7.5 Hz, 1H); 13C NMR (75 MHz, CDCl3),
d (ppm): 29.2, 53.4, 54.0, 119.1, 122.9, 124.6, 126.0, 126.3, 126.4,
127.0, 128.1, 129.0, 129.3, 129.4, 132.0, 132.1, 132.2, 133.2, 134.2,134.3, 154.3, 162.1, 167.5. HRMS (ESI-TOF) calcd for C25H20BrN2O2
[MþH]þ: 459.0703; found: 459.0701.
4.3. General experimental procedure for the tandem 1,5-
hydride transfer/cyclization process
Amixture of the substrate 1 (0.2mmol) and Sc(OTf)3 (0.06mmol
for 1aeh, 0.01mmol for 1ien) in 4.0 mL freshly distilledmesitylene
was heated to 190 C in a sealed-tube under argon atmosphere until
the TLC analysis showed the completion of the reaction. The mix-
ture was then cooled to room temperature after which it was pu-
riﬁed by ﬂash chromatography on silica gel using petroleum ether/
ethyl acetate to give the corresponding product 2.
4.3.1. 2-Phenyl-10,20,30,40,4a0,60-hexahydro-5H-spiro[oxazole-4,50-pyr-
ido[1,2-a]quinolin]-5-one (2a). Colorless oil, yield 90%; 69:31 dr; 1H
NMR (300 MHz, CDCl3), d (majorþminor) (ppm): 1.30e1.45 (m, 2H),
1.60e1.85 (m, 4H), 2.80e2.88 (m,1.7H), 3.07 (s, 0.3H), 3.33e3.50 (m,
2H), 4.13e4.17 (m, 1H), 6.75e6.80 (m, 1H), 6.99e7.04 (m, 2H),
7.21e7.26 (m, 1H), 7.44e7.58 (m, 3H), 8.05e8.08 (m, 2H); 13C NMR
(75 MHz, CDCl3), d (ppm): 23.4, 23.7, 24.6, 25.1, 26.6, 26.9, 35.7, 37.2,
48.5, 48.8, 60.2, 60.7, 69.1, 70.6, 113.1, 113.7, 118.0, 118.1, 118.2, 119.4,
125.4,125.6,127.7,127.8,127.9,128.2,128.4,128.5,128.7,129.3,129.4,
132.7, 132.8, 144.9, 145.0, 161.0, 161.1, 175.8, 179.0. HRMS (ESI-TOF)
calcd for C21H21N2O2 [MþH]þ: 333.1598; found: 333.1607.
4.3.2. 2-o-Tolyl-10,20,30,40,4a0,60-hexahydro-5H-spiro[oxazole-4,50-
pyrido[1,2-a]quinolin]-5-one (2b). Colorless oil, yield 72%; 69:31 dr;
1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm): 1.40e1.44 (m,
2H), 1.64e1.85 (m, 4H), 2.57 (s, 2H), 2.66 (s, 1H), 2.81e3.03 (m, 2H),
3.35e3.45 (m, 2H), 4.10e4.14 (m,1H), 6.72e6.76 (m,1H), 6.96e7.00
(m, 2H), 7.18e7.20 (m, 1H), 7.24e7.33 (m, 2H), 7.39e7.44 (m, 1H),
7.85e7.88 (m, 1H); 13C NMR (75 MHz, CDCl3), d (ppm): 21.9, 22.1,
23.6, 23.8, 24.9, 25.1, 26.9, 27.0, 36.1, 37.2, 48.5, 48.8, 60.2, 60.6, 69.3,
70.5, 113.1, 113.5, 118.0, 118.1, 119.4, 124.9, 125.8, 126.0, 127.7, 127.9,
129.3, 129.4, 130.0, 130.1, 131.5, 131.7, 131.8, 131.9, 139.4, 139.6, 145.1,
145.2, 161.5, 161.6, 175.9, 179.2. HRMS (ESI-TOF) calcd for
C22H23N2O2 [MþH]þ: 347.1754; found: 347.1763.
4.3.3. 2-p-Tolyl-10,20,30,40,4a0,60-hexahydro-5H-spiro[oxazole-4,50-
pyrido[1,2-a]quinolin]-5-one (2c). Colorless oil, yield 83%; 66:34 dr;
1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm): 1.39e1.42 (m,
2H), 1.69e1.80 (m, 4H), 2.42e2.45 (m, 3H), 2.78e2.86 (m, 2H),
3.32e3.37 (m, 1.3H), 3.42e3.48 (m, 0.7H), 4.12e4.16 (m, 1H),
6.73e6.78 (m, 1H), 6.98e7.03 (m, 2H), 7.17e7.32 (m, 3H), 7.92e7.95
(m, 2H); 13C NMR (75 MHz, CDCl3), d (ppm): 21.6, 21.7, 23.4, 23.8,
24.7, 25.1, 26.7, 26.9, 35.8, 37.3, 48.5, 48.9, 60.3, 60.7, 69.0, 70.5, 113.1,
113.8, 118.1, 118.2, 119.5, 122.7, 122.8, 127.7, 127.9, 128.0, 128.3, 129.2,
129.3,129.4,129.5,143.5,143.6,145.0,145.1,161.1,176.0,179.3. HRMS
(ESI-TOF) calcd for C22H23N2O2 [MþH]þ: 347.1754; found: 347.1757.
4.3.4. 2-(4-Methoxyphenyl)-10,20,30,40,4a0,60-hexahydro-5H-spiro
[oxazole-4,50-pyrido[1,2-a]quinolin]-5-one (2d). Colorless oil, yield
61%; 70:30 dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm):
1.38e1.44 (m, 2H), 1.56e1.80 (m, 4H), 2.77e2.85 (m, 2H),
3.31e3.34 (m, 1.4H), 3.35e3.46 (m, 0.6H), 3.86 (s, 2H), 3.88 (s, 1H),
4.11e4.15 (m, 1H), 6.72e6.77 (m, 1H), 6.92e7.02 (m, 4H), 7.16e7.18
(m, 1H), 7.96e8.00 (m, 2H); 13C NMR (75 MHz, CDCl3), d (ppm):
23.4, 23.8, 24.7, 25.2, 26.7, 26.9, 35.9, 37.4, 48.6, 48.9, 55.3, 55.4,
60.4, 60.8, 68.9, 70.5, 113.1, 113.8, 113.9, 114.1, 117.8, 117.9, 118.1,
118.2, 119.6, 127.6, 127.8, 129.1, 129.3, 129.4, 129.9, 130.2, 145.0,
145.1, 160.7, 161.0, 163.1, 163.2, 176.1, 179.3. HRMS (ESI-TOF) calcd
for C22H23N2O3 [MþH]þ: 363.1703; found: 363.1706.
4.3.5. 2-(3-Fluorophenyl)-10,20,30,40,4a0,60-hexahydro-5H-spiro[ox-
azole-4,50-pyrido[1,2-a]quinolin]-5-one (2e). Colorless oil, yield
W.-Y. Han et al. / Tetrahedron 69 (2013) 7019e7025702492%; 68:32 dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm):
1.28e1.44 (m, 2H), 1.58e1.85 (m, 4H), 2.80e2.87 (m, 1.7H), 3.07 (s,
0.3H), 3.30e3.49 (m, 2H), 4.12e4.16 (m, 1H), 6.74e6.79 (m, 1H),
6.98e7.03 (m, 2H), 7.18e7.29 (m, 2H), 7.43e7.47 (m, 1H), 7.74e7.84
(m, 2H); 13C NMR (75 MHz, CDCl3), d (ppm): 23.4, 23.8, 24.6, 25.1,
26.6, 26.9, 35.6, 37.2, 48.5, 48.9, 60.3, 60.7, 69.4, 70.8, 113.1, 113.8,
115.0, 115.1, 115.4, 118.1, 118.3, 119.2, 119.7, 120.0, 124.0, 124.1, 127.8,
128.0, 129.3, 129.4, 130.3, 130.4, 130.5, 144.9, 145.0, 160.1, 160.9,
164.1, 164.2, 175.5, 178.6. HRMS (ESI-TOF) calcd for C21H20FN2O2
[MþH]þ: 351.1503; found: 351.1508.
4.3.6. 2-(4-Bromophenyl)-10,20,30,40,4a0,60-hexahydro-5H-spiro[ox-
azole-4,50-pyrido[1,2-a]quinolin]-5-one (2f). Colorless oil, yield 64%;
65:35 dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm):
1.33e1.38 (m, 2H), 1.55e1.83 (m, 4H), 2.77e2.85 (m, 2H), 3.28e3.35
(m,1.3H), 3.28e3.47 (m, 0.7H), 4.11e4.15 (m,1H), 6.72e6.77 (m,1H),
6.97e7.02 (m, 2H), 7.16e7.21 (m, 1H), 7.58e7.64 (m, 2H), 7.87e7.91
(m, 2H); 13C NMR (75 MHz, CDCl3), d (ppm): 23.4, 23.8, 24.5, 25.1,
26.6, 27.0, 35.6, 37.2, 48.5, 48.9, 60.3, 60.7, 69.3, 70.8, 113.1, 113.8,
117.9, 118.1, 118.3, 119.3, 124.4, 124.5, 127.7, 127.8, 127.9, 129.3, 129.4,
129.7, 131.9, 132.1, 144.9, 145.0, 160.4, 175.6, 178.7. HRMS (ESI-TOF)
calcd for C21H20BrN2O2 [MþH]þ: 411.0703; found: 411.0690.
4.3.7. 20-Phenyl-2,4,4a,6-tetrahydro-1H,50H-spiro[[1,4] oxazino[4,3-
a]quinoline-5,40-oxazol]-50-one (2g). Colorless oil, yield 37%; 57:43
dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm): 2.83e3.06
(m, 2H), 3.25e3.37 (m,1H), 3.43e3.48 (m, 2H), 3.73e3.79 (m, 2.6H),
3.97e3.79 (m, 1.4H), 6.82e6.83 (m, 1H), 6.93e6.95 (m, 1H),
7.01e7.03 (m, 1H), 7.22e7.26 (m, 1H), 7.47e7.61 (m, 3H), 8.02e8.05
(m, 2H); 13C NMR (75 MHz, CDCl3), d (ppm): 36.3, 37.7, 46.3, 46.9,
58.0, 58.1, 66.6, 66.8, 67.0, 67.3, 68.2, 112.4, 113.0, 118.1, 119.2, 119.3,
119.4, 125.3, 125.4, 127.9, 128.0, 128.1, 128.4, 128.7, 128.9, 129.5,
129.6, 133.0, 133.1, 144.4, 144.7, 161.5, 161.9, 175.0, 178.3. HRMS (ESI-
TOF) calcd for C20H19N2O3 [MþH]þ: 335.1390; found: 335.1392.
4.3.8. 20-(3-Fluorophenyl)-2,4,4a,6-tetrahydro-1H,50H-spiro[[1,4]ox-
azino[4,3-a]quinoline-5,40-oxazol]-50-one (2h). Colorless oil, yield
78%; 63:37 dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm):
2.83e3.06 (m, 2H), 3.25e3.36 (m, 1H), 3.44e3.59 (m, 2H),
3.73e3.79 (m, 2.6H), 3.99 (s, 1.4H), 6.83e6.84 (m, 1H), 6.94e6.96
(m, 1H), 7.02e7.04 (m, 1H), 7.23e7.46 (m, 3H), 7.72e7.75 (m, 1H),
7.80e7.83 (m, 1H); 13C NMR (75 MHz, CDCl3), d (ppm): 36.1, 37.6,
46.2, 46.8, 57.9, 58.0, 66.7, 66.9, 67.1, 68.3, 112.4, 113.0, 115.1, 115.4,
119.3, 119.4, 120.0, 120.2, 123.8, 123.9, 124.0, 124.1, 127.9, 128.0,
129.4, 129.6, 130.4, 130.5, 130.6, 144.3, 144.5, 160.9, 161.0, 164.2,
164.3, 174.5, 177.8. HRMS (ESI-TOF) calcd for C20H18FN2O3 [MþH]þ:
353.1296; found: 353.1298.
4.3.9. 20-Phenyl-6,7,11b,13-tetrahydro-50H-spiro[isoquinolino [2,1-a]
quinoline-12,40-oxazol]-50-one (2i). Colorless oil, yield 97%; 70:30
dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm): 2.67e2.72
(m, 1H), 3.02e3.08 (m, 0.8H), 3.22e3.28 (m, 1.5H), 3.40e3.44 (m,
0.7H), 3.54e3.80 (m, 1H), 3.98e4.02 (m, 1H), 4.81 (s, 0.3H), 4.86 (s,
0.7H), 6.83e7.03 (m, 3H), 7.13e7.23 (m, 5H), 7.28e7.48 (m, 3H), 7.77
(d, J¼7.5 Hz, 1.4H), 7.93 (d, J¼7.5 Hz, 0.6H); 13C NMR (75 MHz,
CDCl3), d (ppm): 29.9, 30.2, 36.1, 37.2, 42.9, 45.6, 62.2, 62.7, 71.2,
73.0, 112.5, 114.6, 117.7, 118.2, 124.8, 126.3, 127.3, 127.4, 127.6, 127.7,
127.8, 128.4, 128.5, 128.7, 128.8, 129.2, 129.3, 132.4, 132.6, 137.4,
146.0, 146.5, 160.4, 176.5, 179.5. HRMS (ESI-TOF) calcd for
C25H21N2O2 [MþH]þ: 381.1598; found: 381.1585.
4.3.10. 20-o-Tolyl-6,7,11b,13-tetrahydro-50H-spiro [isoquinolino[2,1-
a]quinoline-12,40-oxazol]-50-one (2j). Colorless oil, yield 99%; 71:29
dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm): 2.24 (s,
2.1H), 2.58 (s, 0.9H), 2.69e2.74 (m, 1H), 3.04e3.10 (m, 0.7H),
3.18e3.28 (m, 2.3H), 3.39e3.80 (m, 1H), 3.99e4.02 (m, 1H), 4.83 (s,0.3H), 4.88 (s, 0.7H), 6.85e6.93 (m, 2H), 7.11e7.34 (m, 9H), 7.55 (d,
J¼7.5 Hz, 0.7H), 7.71 (d, J¼7.5 Hz, 0.3); 13C NMR (75 MHz, CDCl3),
d (ppm): 21.1, 21.8, 29.9, 30.2, 36.4, 37.3, 43.0, 45.2, 62.0, 62.5, 71.1,
73.2, 112.6, 114.5, 117.8, 125.6, 125.8, 126.3, 127.2, 127.3, 127.4, 127.5,
127.6,128.0,128.8,129.0,129.6,129.7,131.2,131.4,131.5,137.5,138.8,
146.0, 161.0, 161.3, 176.6, 179.8. HRMS (ESI-TOF) calcd for
C26H23N2O2 [MþH]þ: 395.1754; found: 395.1729.
4.3.11. 20-p-Tolyl-6,7,11b,13-tetrahydro-50H-spiro [isoquinolino[2,1-a]
quinoline-12,40-oxazol]-50-one (2k). Colorless oil, yield 97%; 73:27
dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm): 2.37 (s,
2.1H), 2.45 (s, 0.9H), 2.67e2.72 (m, 1H), 3.01e3.07 (m, 0.8H),
3.22e3.25 (m, 1.5H), 3.28e3.29 (m, 0.7H), 3.40e4.02 (m, 2H), 4.80
(s, 0.3H), 4.84 (s, 0.7H), 6.82e6.85 (m, 1H), 6.90e7.02 (m, 2H),
7.12e7.30 (m, 7H), 7.66 (d, J¼8.1 Hz, 1.4H), 7.82 (d, J¼8.1 Hz, 0.6H);
13C NMR (75 MHz, CDCl3), d (ppm): 21.5, 21.6, 29.9, 30.2, 36.1, 37.2,
42.9, 45.6, 62.1, 62.6, 71.1, 72.9, 112.5, 114.5, 117.7, 118.2, 118.9, 122.6,
124.8,126.2,127.3,127.4,127.6,127.7,127.8,128.3,128.8,129.1,129.2,
129.4, 131.3, 137.4, 143.1, 143.3, 146.0, 160.4, 176.7, 179.6. HRMS (ESI-
TOF) calcd for C26H23N2O2 [MþH]þ: 395.1754; found: 395.1731.
4.3.12. 20-(4-Methoxyphenyl)-6,7,11b,13-tetrahydro-50H-spiro [isoqui-
nolino[2,1-a]quinoline-12,40-oxazol]-50-one (2l). Colorless oil, yield
94%; 73:27 dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm):
2.66e2.71 (m,1H), 3.00e3.06 (m, 0.7H), 3.24e3.78 (m, 3.3H), 3.81 (s,
2.1H), 3.87 (s, 0.9H), 3.99e4.01 (m,1H), 4.77 (s, 0.3H), 4.82 (s, 0.71H),
6.81e7.02 (m, 8H), 7.11e7.27 (m, 2H), 7.70 (d, J¼8.7 Hz, 1.4H), 7.89 (d,
J¼8.7 Hz, 0.6H); 13C NMR (75 MHz, CDCl3), d (ppm): 30.1, 30.2, 36.2,
37.2, 42.9, 45.6, 55.2, 55.3, 62.1, 62.6, 71.1, 72.8, 112.4, 113.9, 114.1,
114.5, 117.6, 118.2, 118.9, 126.2, 127.2, 127.3, 127.6, 127.7, 127.8, 128.3,
128.8,129.2,129.3,129.4,129.6,137.5,146.0,146.5,160.0,162.8,163.0,
176.8, 179.7. HRMS (ESI-TOF) calcd for C26H23N2O3 [MþH]þ:
411.1703; found: 411.1694.
4.3.13. 20-(3-Fluorophenyl)-6,7,11b,13-tetrahydro-50H-spiro [isoquino-
lino[2,1-a]quinoline-12,40-oxazol]-50-one (2m). Colorless oil, yield
99%; 69:31 dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm):
2.68e2.73 (m, 1H), 3.02e3.08 (m, 0.7H), 3.16e3.28 (m, 1.6H),
3.42e3.43 (m, 0.7H), 3.54e3.80 (m, 1H), 3.98e4.02 (m, 1H), 4.81 (s,
0.3H), 4.86 (s, 0.7H), 6.82e6.85 (m,1H), 6.90e7.28 (m, 9H), 7.33e7.55
(m, 2H); 13C NMR (75 MHz, CDCl3), d (ppm): 29.9, 30.2, 36.0, 37.1,
42.9, 45.6, 62.3, 62.7, 71.3, 73.2, 112.6, 114.6, 114.7, 117.8, 118.3, 123.3,
123.4, 124.8, 126.4, 127.4, 127.5, 127.7, 127.8, 127.9, 128.5, 128.9, 129.2,
129.3, 130.4, 137.4, 145.9, 146.4, 160.8, 164.1, 164.2, 176.1, 179.1. HRMS
(ESI-TOF) calcd for C25H20FN2O2 [MþH]þ: 399.1503; found: 399.1501.
4.3.14. 20-(4-Bromophenyl)-6,7,11b,13-tetrahydro-50H-spiro [isoquino-
lino[2,1-a]quinoline-12,40-oxazol]-50-one (2n). Colorless oil, yield 99%;
70:30 dr; 1H NMR (300 MHz, CDCl3), d (majorþminor) (ppm):
2.66e2.71 (m, 1H), 3.01e3.07 (m, 0.7H), 3.15e3.25 (m, 1.6H),
3.41e3.42 (m, 0.7H), 3.52e3.78 (m, 1H), 3.98e4.01 (m, 1H), 4.79 (s,
0.3H), 4.84 (s, 0.7H), 6.81e6.82 (m, 1H), 6.89e7.26 (m, 7H), 7.50 (d,
J¼8.7 Hz, 1.4H), 7.59e7.62 (m, 2H), 7.75 (d, J¼8.7 Hz, 0.6H); 13C NMR
(75 MHz, CDCl3), d (ppm): 29.8, 30.1, 35.9, 37.0, 42.9, 45.5, 62.2, 62.6,
71.2, 73.1, 112.6, 114.5, 117.8, 118.2, 118.7, 124.8, 126.3, 127.4, 127.5,
127.7, 127.8, 128.4, 128.8, 128.9, 129.0, 129.1, 129.2, 131.9, 132.0, 137.3,
145.8, 146.3, 159.6, 159.7, 176.1, 179.1. HRMS (ESI-TOF) calcd for
C25H20BrN2O2 [MþH]þ: 459.0703; found: 459.0688.
4.4. Experimental procedure for the transformation of 2i, 2k,
and 2n to the corresponding ring opening compounds
A solution of compound 2i, 2k or 2m (0.2mmol) inMeOH (3mL)
was stirred at 0 C for 3 min, then MeONa (0.5 mmol) was added,
respectively. The mixture was allowed to warm to room tempera-
ture and stirred for 10 min. After cooling to 0 C, the reaction was
W.-Y. Han et al. / Tetrahedron 69 (2013) 7019e7025 7025quenchedwith saturated aqueousNH4Cl and extractedwith CH2Cl2.
The organic extracts were dried over anhydrous Na2SO4 and con-
centrated by rotary evaporation. The residue was puriﬁed by ﬂash
chromatography on silica gel using petroleum ether/ethyl acetate to
give the corresponding product (3i, 3k or 3m).
4.4.1. Methyl 12-benzamido-7,11b,12,13-tetrahydro-6H-isoquinolino
[2,1-a]quinoline-12-carboxylate (3i). White foam, yield 95%; 75:25
dr; mp 76.1e77.3 C; 1H NMR (300 MHz, CDCl3), d (majorþminor)
(ppm): 2.71e2.77 (m, 0.2H), 3.06e3.10 (m, 0.8H), 3.19e3.26 (m,
2H), 3.57e3.61 (m, 3H), 3.83e4.03 (m, 2H), 4.09e4.12 (m, 1H), 4.69
(s, 0.8H), 4.96 (s, 0.2H), 6.83e6.90 (m, 3H), 7.05e7.22 (m, 5H),
7.27e7.39 (m, 4H), 7.43e7.59 (m, 2H); 13C NMR (75 MHz, CDCl3),
d (ppm): 26.4, 31.2, 31.8, 35.5, 42.0, 45.7, 52.2, 52.9, 59.8, 61.9, 62.8,
63.5, 111.8, 113.6, 119.2, 122.0, 126.1, 126.3, 126.6, 126.8, 126.9, 127.0,
127.8,127.9,128.5,128.8,130.2,130.3,131.4,131.5,131.6,135.3,143.2,
144.8, 166.5, 167.2, 171.9, 172.5. HRMS (ESI-TOF) calcd for
C26H24N2NaO3 [MþNa]þ: 435.1679; found: 435.1725.
4.4.2. Methyl 12-(4-methylbenzamido)-7,11b,12,13-tetrahydro-6H-
isoquinolino[2,1-a]quinoline-12-carboxylate (3k). White solid, yield
97%; 72:28 dr; mp 95.3e96.7 C; 1H NMR (300 MHz, CDCl3),
d (majorþminor) (ppm): 2.34 (s, 2.2H), 2.37 (s, 0.8H), 2.71e2.77 (m,
0.3H), 3.03e3.07 (m, 0.7H), 3.17e3.24 (m, 2H), 3.56 (s, 0.7H), 3.59 (s,
2.3H), 3.81e4.09 (m, 3H), 4.67 (s, 0.7H), 4.94 (s, 0.3H), 6.76e7.05 (m,
4H), 7.14e7.30 (m, 6H), 7.47 (d, J¼8.1 Hz, 1.4H), 7.57 (d, J¼8.1 Hz,
0.6H), 7.65 (br s, 1H); 13C NMR (75 MHz, CDCl3), d (ppm): 21.3, 21.4,
26.3, 31.1, 31.8, 35.5, 41.9, 45.6, 52.2, 52.9, 59.6, 61.8, 62.7, 63.4,111.8,
113.6,119.1,119.4,122.0,126.0,126.3,126.6,126.8,126.9,127.0,127.3,
127.8, 127.9, 128.8, 129.1, 129.4, 130.2, 130.3, 135.3, 141.9, 144.8,
166.4, 167.1, 171.9, 172.6. HRMS (ESI-TOF) calcd for C27H26N2NaO3
[MþNa]þ: 449.1836; found: 449.1859.
4.4.3. Methyl 12-(4-bromobenzamido)-7,11b,12,13-tetrahydro-6H-iso-
quinolino[2,1-a]quinoline-12-carboxylate (3n). White solid, yield 95%;
70:30 dr; mp 105.0e106.3 C; 1H NMR (300 MHz, CDCl3),
d (majorþminor) (ppm): 2.71e3.22 (m, 3H), 3.53 (s, 0.9H), 3.60 (s,
2.1H), 3.78e4.07 (m, 3H), 4.67 (s, 0.7H), 4.94 (s, 0.3H), 6.73e6.89 (m,
3H), 7.02e7.30 (m, 5H), 7.39e7.51 (m, 4H), 7.66 (br s, 1H); 13C NMR
(75 MHz, CDCl3), d (ppm): 26.2, 31.2, 31.5, 35.4, 41.9, 45.7, 52.3, 53.0,
59.6, 61.8, 62.9, 63.4,111.8, 113.8,119.3,121.8,125.1, 126.1,126.4,126.7,
127.1, 127.4, 127.8, 127.9, 128.4, 128.6, 128.8, 129.5, 130.3, 131.4, 131.7,
135.2,142.9, 144.7, 165.5, 166.3, 171.6, 172.4. HRMS (ESI-TOF) calcd for
C26H23BrN2NaO3 [MþNa]þ: 513.0784; found: 513.0790.
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